Genmab A (GMAB) Other Non-Current Liabilities (2019 - 2020)
Genmab A (GMAB) posted Other Non-Current Liabilities of $4.0 for Q3 2020, up 100.0% on a QoQ basis from $2.0 in Q4 2019, and down 100.0% year-over-year from $1.9 million in Q4 2019.
Genmab A (GMAB) Other Non-Current Liabilities (2019 - 2020) Analysis & Trends
Genmab A's Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $4.0 for Q3 2020.
- Quarterly Other Non-Current Liabilities fell 100.0% year-over-year to $4.0 in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $4.0 (down 100.0% YoY) and the FY2019 annual result came in at $2.0, changed N/A from the prior year.
- Other Non-Current Liabilities was $4.0 for Q3 2020 at Genmab A, up from $2.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $1.9 million in Q3 2019 and bottomed at $2.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Genmab A | 1.89 Bn | 366.92 Mn | 831.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 4.00 |
| Dec 31, 2019 | 2.00 |
| Sep 30, 2019 | 1.86 Mn |